



Oral Poster Session

Friday, May 30, 2025

1. Autoimmune Disease

16:40-17:40		Su Cheol Park (Korea Cancer Center Hospital), Ja Kyung Kim (Yonsei Univ.)
OP-1 16:40-16:50	Constructing a Protein Interaction Network for Autoimmune Liver Diseases Using Protein-Protein Ratio Exposures: Insights from a Mendelian Randomization Study	Dianzhe Tian (Peking Union Medical College Hospital, China)
OP-2 16:50-17:00	Epidemiology, Treatment Response, and Genetic Characteristics of Autoimmune Liver Diseases: A Retrospective and Prospective Cohort Study	Young Chang (Soonchunhyang Univ.)
OP-3 17:00-17:10	Risk Factors for Predicting Incomplete Treatment Response in Patients with Primary Biliary Cholangitis: A Korean Multicenter Cohort Study	Soon Kyu Lee (The Catholic Univ. of Korea)
OP-4 17:10-17:20	Clinical Statement for the Diagnosis and Management of PBC-AIH Overlap 2024: Japanese Experience	Atsumasa Komori (NHO Nagasaki Medical Center, Japan)
OP-5 17:20-17:30	Intrahepatic Infiltration of Activated Regulatory T Cells Is Associated with the Degree of Inflammation in Autoimmune Hepatitis	Mi Hyun Kwon (The Catholic Univ. of Korea)
OP-6 17:30-17:40	Prevalence, Incidence, and Risk Factors of Hepatic Cysts	Kang Seo (Seoul National Univ.)

2. MASLD & ALD, Basic

16:40-17:40		Yoon Mee Yang (Kangwon National Univ.), Wonhyo Seo (Ewha Womans Univ.)
OP-7 16:40-16:50	Liver Kinome Profiling Identifies PS1145-IKK Inhibition as a Potential Therapeutic Strategy for Systemic Inflammation in Alcohol-Associated Liver Diseases	Manisha Yadav (Institute of Liver and Biliary Sciences, India)
OP-8 16:50-17:00	Adenosine Triphosphate-Binding Pocket Inhibitor for Mixed Lineage Kinase Domain-Like Protein Attenuated Alcoholic Liver Disease via Necroptosis-Independent Pathway	Seung Min Lee (Hanyang Univ.)

2. MASLD & ALD, Basic

OP-9 17:00-17:10	Polyethylene Glycol Relieves Hangover Symptoms and Protects Liver and Gut by Preventing Intestinal Absorption of Alcohol <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
OP-10 17:10-17:20	GINS2 Accelerated Non-Alcoholic Fatty Liver Disease via Regulating TFEB Mediated Lipophagy <i>Zhaohong Mo (Guangxi Medical Univ., China)</i>
OP-11 17:20-17:30	Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis <i>Hye Young Kim (Hanyang Univ.)</i>
OP-12 17:30-17:40	Treatment with IL-18 Binding Protein Biologics Inhibits Fibrotic Progression in Metabolic Dysfunction-Associated Steatohepatitis <i>Dong-Hyun Kim (Kangwon National Univ.)</i>

3. MASLD, Clinical 1

16:40-17:40 <i>Sung Bum Cho (Chonnam National Univ.), Danbi Lee (Univ. of Ulsan)</i>	
OP-13 16:40-16:50	Improvement of Hepatic Steatosis and Reduction in Cardiovascular Event in Patients with Diabetes Mellitus: A Prospective Study <i>Yoon Seok Lee (Gachon Univ.)</i>
OP-14 16:50-17:00	Sugar-Sweetened Beverage Consumption and Metabolic Dysfunction Associated Steatotic Liver Disease: Exploring Different Types of Beverages <i>Hong Jae Jeon (Chungnam National Univ.)</i>
OP-15 17:00-17:10	Higher Age-Adjusted Skeletal Muscle Index Associated with Severe Hepatic Steatosis and Fibrosis in male MASLD Patients <i>Jang Han Jung (Hallym Univ.)</i>
OP-16 17:10-17:20	Effect of Vitamin E on Liver Stiffness in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Seung Teak Lee (Seoul National Univ.)</i>
OP-17 17:20-17:30	Changing Prevalence and Risks Factors of Metabolic Dysfunction Associated Steatotic Liver Disease during Three Decades in Taiwan <i>Ming-Lun Yeh (National Sun Yat-sen Univ., Taiwan)</i>

3. MASLD, Clinical 1

OP-18 17:30-17:40	Association between Smoking and Clinical Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Tom Ryu (Soonchunhyang Univ.)</i>
-----------------------------	---

4. LC, Clinical & Liver Failure

16:40-17:30 <i>Woo Jin Chung (Keimyung Univ.), Myeong Jun Song (The Catholic Univ. of Korea)</i>	
OP-19 16:40-16:50	Impact of Cardiometabolic Risk Factors on Hepatic Fibrosis and Clinical Outcomes in MASLD: A Population-Based Multi-Cohort Study <i>Eileen L. Yoon (Hanyang Univ.)</i>
OP-20 16:50-17:00	Spleen Stiffness Measurement Using New Spleen-Dedicated Fibroscan: Intra/Interobserver Repeatability <i>Heon-Ju Kwon (Sungkyunkwan Univ.)</i>
OP-21 17:00-17:10	Validation and Comparative Performance of Postoperative Risk Scores in Cirrhotic Patients: A Korean Cohort Study <i>Hee Sun Cho (The Catholic Univ. of Korea)</i>
OP-22 17:10-17:20	Transplantation of Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Decompensated Liver Cirrhosis: A Real-World Evidence Study in a Population-Based Cohort <i>Seul Ki Han (Yonsei Univ. Wonju)</i>
OP-23 17:20-17:30	Impact of Hepatic Encephalopathy on Prognosis in Cirrhotic Patients with Acute Decompensation: The Crucial Role of Underlying Liver Function and Coagulation Failure <i>Junghee Kim (Hallym Univ.)</i>

5. Liver Transplantation 1

16:40-17:40 <i>Jeong-Ik Park (Univ. of Ulsan), Tae-Seok Kim (Keimyung Univ.)</i>	
OP-24 16:40-16:50	Renal Recovery Benefit of Living Donor Compared to Deceased Donor Liver Transplantation in High-MELD Recipients: A Propensity Score-Matched Study <i>Min-Ha Choi (Univ. of Ulsan)</i>

5. Liver Transplantation 1

OP-25 16:50-17:00	Impact of Radiation Therapy on Biliary Complications in Liver Transplant HCC Recipients Withoma: A Propensity Score-Matched Analysis <i>Min-Ha Choi (Univ. of Ulsan)</i>
OP-26 17:00-17:10	ABO Incompatible Dual Graft Living Donor Liver Transplantation Using Modified Extended Left Lateral Graft: Case Report <i>Min-Ha Choi (Univ. of Ulsan)</i>
OP-27 17:10-17:20	Liver Transplantation Can Be a Treatment Option for Patients with Cholangiocarcinoma: A Single-Center Experience <i>Youngju Ryu (Sungkyunkwan Univ.)</i>
OP-28 17:20-17:30	Bile Duct Complication and Impact on Outcomes after Living-Donor Liver Transplant: A Machine Learning Approach <i>Derizal Derizal (Ip Trisakti, Indonesia)</i>
OP-29 17:30-17:40	Outcomes and Risk Factors for De Novo Major Depressive Disorder after Liver Transplantation: Nested Case-Control Study <i>Young Jin Yoo (Yonsei Univ.)</i>

6. Liver Cancer, Basic 1

16:40-17:40*Hyun Phil Shin (Kyung Hee Univ.), Pyoung Jae Park (Korea Univ.)*

OP-30 16:40-16:50	Identification of IKBKB as a Novel Regulator of Macrophage Phagocytosis That Enhances Antitumor Immunity in HCC <i>Sze Man Chan (The Hong Kong Polytechnic Univ., Hong Kong)</i>
OP-31 16:50-17:00	Identifying the Key Factors Contributing to the Progress of Liver Fibrosis to Cancer and the Tumor Microenvironment Immunosuppression <i>Hongping Xia (Southeast Univ., China)</i>
OP-32 17:00-17:10	Inhibition of PLD1 Increases Apoptosis in HCC Cells <i>Ha Neul Kim (Chungnam National Univ.)</i>
OP-33 17:10-17:20	Genomic Analysis of Combined Hepatocellular-Cholangiocarcinoma Reveals Common Lineage of Tumor Components with Unique Gene Expression Profile <i>Hyelim Joo (Seoul National Univ.)</i>

6. Liver Cancer, Basic 1

OP-34 17:20-17:30	CRY2 Is an Actionable Target to Modulate Tumor Growth and Stemness in HCC <i>Regina Lo (The Univ. of Hong Kong, Hong Kong)</i>
OP-35 17:30-17:40	PNPLA3 I148M GG Variant Correlates with Poor Tumor Differentiation but Not HCC Risk in MASLD Patients <i>Jaeeun Lee (The Catholic Univ. of Korea)</i>

7. Liver Cancer, Clinical 1

16:40-17:40 <i>Bo Hyun Kim (National Cancer Center), Won Sohn (Sungkyunkwan Univ.)</i>	
OP-36 16:40-16:50	A New Prognostic Index for Patients with Advanced Biliary Tract Cancer Treated with Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index <i>Mara Persano (IRCCS San Raffaele, Italy)</i>
OP-37 16:50-17:00	Mass Spectrometry-Based Proteomics Analysis to Discover Biomarkers in Atezolizumab and Bevacizumab Therapy for Patients with Advanced HCC <i>Eunho Choi (Korea Univ.)</i>
OP-38 17:00-17:10	Development and Validation of a Risk Prediction Model for Patients with HCC Receiving Atezolizumab-Bevacizumab <i>Heechul Nam (The Catholic Univ. of Korea)</i>
OP-39 17:10-17:20	Prognostic Impact of Diabetes and Hypertension on HCC Survival: A 15-Year Registry-Based Analysis <i>Hyeyeon Hong (Univ. of Ulsan)</i>
OP-40 17:20-17:30	Machine Learning-Based Prediction of Clinically Significant Portal Hypertension and Future Hepatic Decompensation in Patients with BCLC-C HCC <i>Ji Won Han (The Catholic Univ. of Korea)</i>
OP-41 17:30-17:40	Bleeding Complications and Survival Outcomes in HCC Patients Treated with Atezolizumab/Bevacizumab: Multicenter Real-World Study <i>Yu Rim Lee (Kyungpook National Univ.)</i>

8. Liver Cancer, Clinical 2

16:40-17:40*Do Seon Song (The Catholic Univ. of Korea), Eun Sun Jang (Seoul National Univ.)***OP-42**

16:40-16:50

The State of Pediatric Malignant Neoplasm of Liver in Korea: Nationwide Cohort Study*Jihye Lim (The Catholic Univ. of Korea)***OP-43**

16:50-17:00

The Role of Transarterial Chemoembolization for Advanced HCC in the Era of Immune Checkpoint Inhibitor*Kyungdeok Bae (Univ. of Ulsan)***OP-44**

17:00-17:10

15-Year Trends in HCC: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry*Songgyung Kim (Univ. of Ulsan)***OP-45**

17:10-17:20

Impact of Endoscopic Retrograde Cholangiopancreatography and Radiation Therapy in HCC Patients with Bile Duct Invasion Receiving Atezolizumab plus Bevacizumab*Kiyoun Yi (Pusan National Univ.)***OP-46**

17:20-17:30

RT Combination in Atezolizumab and Bevacizumab Benefits HCC with HBV Etiology*Kwon Yong Tak (The Catholic Univ. of Korea)***OP-47**

17:30-17:40

Decision Tree Modeling of Exosomal miR-30a-5p for Predicting Response to Atezolizumab and Bevacizumab in Advanced HCC*Ha Seok Lee (Korea Univ.)*

9. Liver Surgery

16:40-17:40*Nam Kyu Choi (Chosun Univ.), Jai Young Cho (Seoul National Univ.)***OP-48**

16:40-16:50

Caregiver Perception, Knowledge, and Attitude toward Postoperative Recovery among Patients with Liver Disease*Lintong Hottua Simbolon (The Pranala Institute, Indonesia)***OP-49**

16:50-17:00

Divergent Impact of Preoperative Platelet Count Abnormalities on Long-Term Outcomes after Curative Hepatic Resection for HCC: A Multi-Institutional Analysis of 3,116 Patients*Han Liu (First Hospital of Jilin Univ., China)*

9. Liver Surgery

OP-50 17:00-17:10	Superior Prognostic Performance of the AFP Model Over Milan Criteria Following Hepatic Resection for HCC: A Multi-Institutional Analysis <i>Han Liu (First Hospital of Jilin Univ., China)</i>
OP-51 17:10-17:20	Development and Validation of a Laboratory Risk Score (APASL Score) to Predict Long-Term Survival after Hepatectomy for HCC: A Multicenter Analysis <i>Han Liu (First Hospital of Jilin Univ., China)</i>
OP-52 17:20-17:30	Laparoscopic Hepatectomy for Giant Hepatic Hemangioma: A Vietnamese Center Experience <i>Hieu Le Trung (108 Military Central Hospital, Vietnam)</i>
OP-53 17:30-17:40	Surgical Approach to Supradiaphragmatic IVC Tumor Thrombosis of HCC through Abdominal Cavity by Cutting Diaphragm Vertically without Opening the Pericardium <i>Nyamsuren Ganbileg (National Cancer Center of Mongolia, Mongolia)</i>

10. Liver Cancer, Basic 2

16:40-17:40 <i>Jooho Lee (CHA Univ.), Sung-Eun Kim (Hallym Univ.)</i>	
OP-54 16:40-16:50	Focal Amplification of EGFR Drives Acquired Resistance to Lenvatinib in HCC <i>Ji Young Kim (Sungkyunkwan Univ.)</i>
OP-55 16:50-17:00	A Study on the Development of a Traditional Liver Cancer Mouse Model Using Hydrodynamic Injection <i>HyeonJi Kim (Kyungpook National Univ.)</i>
OP-56 17:00-17:10	Prolonged Lenvatinib Treatment Affects Tumor-Neutrophil Interaction and Contributes to Compromised Immune Checkpoint Blockade Treatment in HCC <i>Yunong Xie (The Chinese Univ. of Hong Kong, Hong Kong)</i>
OP-57 17:10-17:20	IGF2BP1 Promotes Proliferation and Metastasis of HCC via m6A-Modified PEG10 mRNA <i>Qiongguang Huang (Guangxi Medical Univ., China)</i>
OP-58 17:20-17:30	Finding the Role of a Novel Oncogene in Liver Cancer through Hydrodynamic Gene Delivery <i>Ha Gyun Kim (Kyungpook National Univ.)</i>

10. Liver Cancer, Basic 2

OP-59

17:30-17:40

Long Non-coding RNA TUG1 Regulates Multiple Glycolytic Enzymes in HCC Cells via Sponging microRNA-122-5p

Chaiyaboot Ariyachet (Chulalongkorn Univ., Thailand)

Oral Poster Session

Saturday, May 31, 2025

11. HBV

09:30-10:30		Hyun Woong Lee (Yonsei Univ.), Sung-Eun Kim (Hallym Univ.)
OP-60 09:30-09:40	Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: Insights from Nationwide Cohort Study	Hyun Bin Choi (Soonchunhyang Univ.)
OP-61 09:40-09:50	VELLIA®(DA-2803) versus VEMLIDY® for the Treatment of Patients with Chronic Hepatitis B: A Multi-Center, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Study	Jeayeon Park (Seoul National Univ.)
OP-62 09:50-10:00	Comparative Risk of Osteoporosis and Fractures in Chronic Hepatitis B Patients: Tenofovir Disoproxil Fumarate versus Entecavir in a Korean Nationwide Cohort	Jisoo Lee (Soonchunhyang Univ.)
OP-63 10:00-10:10	Turning LLMs into Clinical Decision Supporters: Optimizing Prompt Structures for Drug Side Effect Prediction in Chronic Hepatitis B Patients	Jihyun Moon (Handong Global Univ.)
OP-64 10:10-10:20	Longitudinal Renal Function Trajectories in Chronic Hepatitis B Patients on Entecavir or Tenofovir Alafenamide: A Nationwide Population-Based Study in Korea	Jae Hyun Yoon (Chonnam National Univ.)
OP-65 10:20-10:30	Efficacy of Prophylactic Antiviral Therapy in Preventing Hepatitis B Reactivation in Patients with Anti-HBc Antibody Undergoing Daratumumab Treatment	Jaejun Lee (The Catholic Univ. of Korea)

12. MASLD, Clinical 2

09:30-10:30		Tae-Hee Lee (Konyang Univ.), Yong Jin Jung (Seoul National Univ.)
OP-66 09:30-09:40	MEFV Dysfunction Promotes HCC Progression via Inflammasome Activation	Hyunjae Shin (Seoul National Univ.)
OP-67 09:40-09:50	A Randomized Controlled Trial to Explore the Effect of Modulation of Gut Microbiota on Liver Fibrosis in Patients with Non-Alcoholic Steatohepatitis	Aashal Bhavesh Shah (GMERS Medical College and Civil Hospital, India)

12. MASLD, Clinical 2

OP-68 09:50-10:00	Impaired Sensitivity to Thyroid Hormones Is Associated with Cardiovascular Outcomes in Euthyroid Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Yeonjung Ha (CHA Univ.)</i>
OP-69 10:00-10:10	Cancer Risk and Its Non-Invasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis <i>Hana Park (Univ. of Ulsan)</i>
OP-70 10:10-10:20	Aspirin and HCC Risk in MASLD: Nationwide Cohort Study with Genetic Risk Analysis <i>Min Kyung Park (Seoul National Univ.)</i>
OP-71 10:20-10:30	PNPLA3 p.I148M Polymorphism Increases Risk of Liver Fibrosis in Breast Cancer Patients Receiving Tamoxifen Therapy <i>Sangdeok Shin (Sungkyunkwan Univ.)</i>

13. Liver Cancer, Clinical 3

09:30-10:30 <i>Sang Youn Hwang (Dongnam Institute of Radiological & Medical Sciences), Bo Hyun Kim (National Cancer Center)</i>	
OP-72 09:30-09:40	Impact of Metformin Administration on Clinical Outcomes in Patients with HCC Treated with Atezolizumab plus Bevacizumab <i>Yoonseok Lee (Gachon Univ.)</i>
OP-73 09:40-09:50	Comparative Analysis of Therapeutic Strategies in Combined Hepatocellular-Cholangiocarcinoma <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
OP-74 09:50-10:00	Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage HCC <i>Eun Min Kim (Yonsei Univ.)</i>
OP-75 10:00-10:10	Effect of Combining Serum Alpha-Fetoprotein with LI-RADS v2018 on Gadobutate-Enhanced MRI in the Diagnosis and Prognostication of HCC <i>Dong Hwan Kim (Univ. of Ulsan)</i>

13. Liver Cancer, Clinical 3

OP-76 10:10-10:20	Association between Young Age and Prognosis of HCC: A Large Single-Center Matched Study <i>Sang-Hoon Kim (Univ. of Ulsan)</i>
OP-77 10:20-10:30	Real-World Incidence and Predictive Factors of Variceal Bleeding in HCC Patients Treated with Atezolizumab-Bevacizumab <i>Jeong Eun Song (Daegu Catholic Univ.)</i>

14. HBV & LC, Basic

09:30-10:30		<i>Ryu Soo Hyung (SSOK Internal Medicine Clinic), Byung Seok Kim (Daegu Catholic Univ.)</i>
OP-78 09:30-09:40	Liver on the Mend: CRISPR-Based Gene Therapy as a Game-Changer for Genetic Hepatic Diseases <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>	
OP-79 09:40-09:50	In Silico Design and Evaluation of siRNA Targeting HBV S and C Genes for Hepatitis B Treatment <i>Reny Rosalina (Universitas Palangka Raya, Indonesia)</i>	
OP-80 09:50-10:00	cccDNA as a Therapeutic Target in Hepatitis B Virus Infection: Mechanisms and Drug Development - A Systematic Review <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>	
OP-81 10:00-10:10	In Patients with HCC, Autologous NK Cell Immunotherapy after Transarterial-Chemoembolization (TACE) Increased Disease-Free Survival and Improved Liver Fibrosis: Proof of Concept Study <i>Sooyeon Oh (CHA Univ.)</i>	
OP-82 10:10-10:20	Intrahepatic B Cells Aggravate Liver Fibrosis by Producing Pro-fibrotic Mediators through CD40-mediated NKT Interaction <i>Jihyo Byun (KAIST)</i>	
OP-83 10:20-10:30	Verification of Liver Sinusoid Endothelial Cell Normalization and Hepatic Progenitor Cell Activation Efficacy of Bone Marrow- Mesenchymal Stem Cell Derived Extracellular Vesicles <i>Mi Ra Lee (Yonsei Univ. Wonju)</i>	

15. Others

09:30-10:30

Woo Jin Chung (Keimyung Univ.), In Hee Kim (Jeonbuk National Univ.)

OP-84 09:30-09:40	ROS Mediated HMGB1-RIPK1 Upregulation Mediates Hepatocellular Injury, Inflammation Promotes Endothelial Dysfunction and Ductal Proliferation in Drug Induced Liver Injury <i>Himanshi Himanshi (Institute of Liver and Biliary Sciences, India)</i>
OP-85 09:40-09:50	STRAP Promotes Drug-Induced Acute Liver Injury via mTOR-Mediated Autophagy <i>Mingbei Zhong (Guangxi Medical Univ., China)</i>
OP-86 09:50-10:00	3D Bioprinted Tubular Hepatobiliary Model Enabling Bile Acid Transport and Drainage <i>Seon-Jin Kim (Pohang Univ. of Science and Technology)</i>
OP-87 10:00-10:10	Targeting Hepatic Stem Cell Niche with Epigenetic Modulators for Accelerated Liver Regeneration in Advanced Hepatic Fibrosis <i>Venkatakrishnan Karunanithi (ACS Medical College and Hospital, India)</i>
OP-88 10:10-10:20	A Prospective Cohort Study of Hepatic and Biliary Complications in Pediatric Patients with Sickle Cell Disease in India <i>Ashishkumar Chaudhari (GMERS Medical College, India)</i>
OP-89 10:20-10:30	The Effectiveness of Abdominal Doppler Ultrasound, Measurement of Abdominal Fat, and the Value of Swm/Att in the Assessment of Liver Disease <i>Soung Won Jeong (Soonchunhyang Univ.)</i>

16. Liver Cancer, Clinical 4

09:30-10:30

Seung Ha Park (Inje Univ.), Hyun Young Woo (Pusan National Univ.)

OP-90 09:30-09:40	Comparative Effectiveness of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in HCC Recurrence and Mortality after Curative Treatment <i>Ji Eun Han (Ajou Univ.)</i>
OP-91 09:40-09:50	The Role of TARE for Bridging and Downstaging of HCC before Resection or Liver Transplant: A Retrospective Analysis <i>Abdullah Alshamrani (Sungkyunkwan Univ.)</i>

16. Liver Cancer, Clinical 4

OP-92 09:50-10:00	Proteinuria and Its Clinical Implications in HCC Patients Treated with Atezolizumab/Bevacizumab: A Multicenter Real-World Study <i>Yu Rim Lee (Kyungpook National Univ.)</i>
OP-93 10:00-10:10	Role of ALBI Score as a Predictive Factor for Mortality in Patients with HCC Undergoing Transarterial Chemoembolization <i>Kyoung A Ko (Sungkyunkwan Univ.)</i>
OP-94 10:10-10:20	The Real Change in Cholangiocarcinoma? A Real-World Experience <i>Stefano Mariani (A.O.U. Cagliari, Italy)</i>
OP-95 10:20-10:30	Efficacy of Lymphadenectomy in Intrahepatic Cholangiocarcinoma <i>In Soo Cho (Keimyung Univ.)</i>

17. Liver Transplantation 2

09:30-10:30 Kwangho Yang (Pusan National Univ.), Hyeyoung Kim (Soonchunhyang Univ.)	
OP-96 09:30-09:40	Clinical Significance of De Novo Malignancy after Liver Transplant: Update on a Single-Center Study <i>Jae-Yoon Kim (Seoul National Univ.)</i>
OP-97 09:40-09:50	Investigating Key Factors of Fatty Liver Disease in Liver Donors <i>E. Ben George (Univ. of Technology and Applied Sciences - Muscat, Oman)</i>
OP-98 09:50-10:00	Xenotransplantation of Pancreatic Islet Cells: A Promising Approach for Type 1 Diabetes Treatment <i>Nodirjon Ruzimurodov (IIHG AS RU, Uzbekistan)</i>
OP-99 10:00-10:10	Ameliorating Effect of Curcumin Loaded Silver Nanoparticles against Liver Transplantation Associated Ischemia-Reperfusion Injury by Downregulating Inflammation and TLR-4/NF- κ B/NLRP3 Signalling Pathway <i>Ekta Yadav (SHUATS, India)</i>
OP-100 10:10-10:20	Machine Perfusion in Marginal Liver Grafts: A Systematic Review of Clinical Impact on Liver Transplantation <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>

17. Liver Transplantation 2

OP-101
10:20-10:30

Comparison of Effectiveness of Mycophenolate Mofetil Associated with Standard Dosage or Reduced-Dose Tacrolimus for Liver Transplantation Immunosuppression

Ulil Albab Habibah (Islamic Univ., Indonesia)

18. Liver Cancer, Basic 3

09:30-10:30

*Hyun Phil Shin (Kyung Hee Univ.), Young-Sun Lee (Korea Univ.)*OP-102
09:30-09:40

Characterization of Diverse Extracellular Nanoparticles and Tumorigenic Relevance in HCC

*Charlotte Jiaqi Lai (Univ. of Hong Kong, Hong Kong)*OP-103
09:40-09:50

Spatial Transcriptomics Uncovers Intratumoral Molecular Heterogeneity in Hepatoblastoma

*In Hye Song (Univ. of Ulsan)*OP-104
09:50-10:00

Differential Infiltration of T-Cell Populations in Tumor and Liver Tissue Predicts Recurrence-Free Survival in Surgically Resected HCC

*Eun Ji Jang (The Catholic Univ. of Korea)*OP-105
10:00-10:10

Visceral Adipose Tissue from Morbid Obesity Patients Promotes the Proliferation of HCC Cells

*Ji Yeon Park (Keimyung Univ.)*OP-106
10:10-10:20

CTC-537E7.3 as a Liver-Specific Biomarker for HCC: Diagnostic and Prognostic Implications

*Se Ha Jang (Ajou Univ.)*OP-107
10:20-10:30

RBBP7 Promotes HCC Progression via Enhancing Small Extracellular Vesicle Secretions

Wing Lam Tam (The Univ. of Hong Kong, Hong Kong)

19. Liver Cancer, Clinical 5

09:30-10:20		Sung Won Lee (The Catholic Univ. of Korea), Hye Won Lee (Yonsei Univ.)
OP-108 09:30-09:40	Clinical Outcomes of Atezolizumab Plus Bevacizumab in Viral and Non-viral Advanced HCC Patients : A Real-World, Multicenter Study	Yeo Wool Kang (Dong-A Univ.)
OP-109 09:40-09:50	Hepatic Perivascular Epithelioid Cell Tumor (PEComa) Mimicking HCC	Sukbae Kim (Dankook Univ.)
OP-110 09:50-10:00	Machine Learning-Based Risk Stratification to Optimize Treatment Selection between Surgical Resection and Liver Transplantation	Hyun Uk Kim (The Catholic Univ. of Korea)
OP-111 10:00-10:10	Clinical Outcomes of 2,000 HCC Patients Treated with Proton Beam Therapy at Single Center: Toward Further Optimized Treatment Strategies	Jeong Ha Lee (Sungkyunkwan Univ.)
OP-112 10:10-10:20	Liver Resection in Stage 0-A HCC in Segments 7/8: A Propensity-Matched Analysis Comparing Open, Laparoscopic, and Robotic Approach	Yunchuan Wang (Guangxi Medical Univ., China)

20. Biliary and Pancreatic Surgery

09:30-10:30		Jong Hoon Park (Daegu Fatima Hospital), Cheon Soo Park (The Catholic Univ. of Korea)
OP-113 09:30-09:40	Robotic-Assisted Surgery for Complex Biliary Strictures: A Prospective Study	John Thomas Arul J S (ACS Medical College and Hospital, India)
OP-114 09:40-09:50	Effect of Head Coring with Lateral Pancreaticojejunostomy on Pancreatic Exocrine Function in Patients with Idiopathic Chronic Pancreatitis – A Prospective Observational Study	Kislay Kant (All India Institute of Medical Sciences, India)
OP-115 09:50-10:00	Terminal Complement Cascade Contributes to the Pathogenesis of Severe Acute Pancreatitis by Intracellular Calcium Overload Induced Pyroptosis	Guandou Yuan (The First Affiliated Hospital of Guangxi Medical Univ., China)

20. Biliary and Pancreatic Surgery

OP-116 10:00-10:10	Immediate Results of Laparoscopic Spleen-Preserving Distal Pancreatectomy: Kimura vs. Warshaw Operation <i>Ilya Vervekin (Pavlov First Saint Petersburg State Medical Univ., Russia)</i>
OP-117 10:10-10:20	Preoperative UGI Scopy: Reducing Post-Cholecystectomy Syndrome and Pain Severity <i>John Thomas Arul J S (ACS Medical College and Hospital, India)</i>
OP-118 10:20-10:30	Comparison of Rectal Indomethacin with Placebo in Reducing the Clinical Progression of Mild and Moderate Acute Pancreatitis to Severe Acute Pancreatitis- A Double Blinded Randomized Controlled Trial <i>Raj Kumar Nagarajan (JIPMER, India)</i>